CN107157998A - The new application of dextromethorphan - Google Patents
The new application of dextromethorphan Download PDFInfo
- Publication number
- CN107157998A CN107157998A CN201710384984.1A CN201710384984A CN107157998A CN 107157998 A CN107157998 A CN 107157998A CN 201710384984 A CN201710384984 A CN 201710384984A CN 107157998 A CN107157998 A CN 107157998A
- Authority
- CN
- China
- Prior art keywords
- dextromethorphan
- injection
- tumour
- cancer
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the new application of dextromethorphan, it is related to application of the dextromethorphan in the medicine for anti-curing oncoma is prepared.Dextromethorphan can substantially suppress the growth of tumour, meanwhile, dextromethorphan is notable to the prevention effect of tumour.
Description
Technical field
The present invention relates to the purposes of pharmaceutical technology field, especially dextromethorphan in preventing and treating tumour medicine is prepared.
Background technology
Dextromethorphan is developed by Roche Holding Ag of Switzerland earliest, is classified as non-by FDA (Food and Drug Adminstration) (FDA) within 1956
Prescription medicine, be typically considered it is a kind of without narcoticness, have no drug resistance, efficiently, safety central antitussive.1961 in the world
Dextromethorphan is decided to be non-narcotic medicine in arcotic meeting, and the World Health Organization thought that " dextromethorphan is that substitution can in 1989
Treat because a kind of antitussive ", therefore people are increasingly intended to be replaced additive stronger codeine treatment to cough with it in recent years
Cough.Even however, the medicine of such high praise is given, it is also recently found that the problem of some are new.Wherein, dextromethorphan is indiscriminate
With being distinct issues the most, the excessive use of dextromethorphan, produce serious nerve, it is spiritual in terms of toxic side effect, it is necessary to
The safe and reasonable for paying attention to dextromethorphan is used.
The content of the invention
Present inventor is surprised to find that in research process：Dextromethorphan is being prepared for preventing and treating tumour
Medicine in new application, it can suppress the growth of tumour cell, reach the purpose of anti-curing oncoma.
As the further optimization of such scheme, the tumour includes but is not limited to Hepatic venous pressure gradient, breast cancer, stomach
Cancer, lung cancer, cancer of pancreas, colon cancer, carcinoma of endometrium, melanoma, oophoroma and prostate cancer.It should be noted that described
Tumour refers to the tumour of α -7nAchR height expression, wherein, α -7 is nAchR major subunit, and nAchR is neural nicotine acetyl
Choline receptor；Height expression refers to that to compare normal cell higher for α -7nAchR protein content or mRNA contents in tumour cell.
Preferably, the effective dose that the dextromethorphan is used in vivo and in vitro is 10~23.33mg/Kg/7 days.
As the further optimization of such scheme, the administering mode of the dextromethorphan is injection, and the injection includes swollen
Intratumor injection, intraperitoneal injection, hypodermic injection or intravenous injection.
As the further optimization of such scheme, the formulation of the dextromethorphan is tablet, capsule, pill, oral
Liquid or injection.
In summary, beneficial effects of the present invention are：
By present invention demonstrates that dextromethorphan can substantially suppress the growth of gross tumor volume and the increase of tumour quantity, to tumour
Prevention effect it is notable.
Brief description of the drawings
Fig. 1 is to use after dextromethorphan, mouse tumor volume growth schematic diagram；
Fig. 2 is the mouse esophageal neoplasm number schematic diagram in C57BL/6 mouse cancer of the esophagus models.
Embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with the drawings and specific embodiments pair
The present invention is described further.It should be noted that reagent, consumptive material, mouse in the present invention etc., unless otherwise instructed,
Obtained with the purchase from market.
The subcutaneous effect into knurl experimental verification dextromethorphan in tumour growth is suppressed of the mouse of embodiment 1
1.1 choose 6 week old, and body weight 18-20g, health status is similar, and the good nude mice 20 of growth conditions is randomly divided into
Four groups, raised in SPF grades of Animal Houses；
1.2 choose the EC9706 cells of logarithmic phase growth, and PBS, which is resuspended, to be counted, and is made 106Individual/ml cell suspension, small
It is subcutaneously injected on the outside of mouse groin, each injection site injection volume is 1ml；
Start within the 7th day after 1.3 hypodermic injections, the size of the knurl of measurement in every 3 days simultaneously calculates tumor volume, treats that knurl volume reaches
To 50mm3When, respectively to two groups of mouse peritoneal injection PBS, dextromethorphans, injection dosage presses body weight 10mg/kg body weight, every 3 days
Injection is once；
When 1.4 experiments proceed to the 5th week, put to death mouse and take knurl, measurement tumorous size and weight, record data.
The data of each measurement tumor size are depicted as growth curve, as shown in figure 1, wherein, 1 is PBS, and 2 be right U.S.
Sha Fen, as a result, it was confirmed that dextromethorphan can substantially suppress the growth of tumour.
Embodiment 2C57 mouse models verify prevention effect of the dextromethorphan to tumour
2.1 experimental animal：The week old C57BL/6 mouse 60 of cleaning grade 4, are randomly divided into two groups, every group 30, standardization is raised
Support cage to feed, 21-25 DEG C of Animal House room temperature, relative humidity 40%-70% is alternately illuminated for 12 hours.Cleaned in cage, mouse is certainly
By feed, water inlet.Daily observation mouse and assessment nutritional status.
2.2 two groups of mouse normal diets and the drinking water for being fed for dissolving 4NQO, wherein control group do not do other processing, experiment
Group mouse peritoneal injection 10mg/kg dextromethorphans, once in a week.Esophageal squamous cell tumour occurs after 16 weeks, is fed within latter 12 weeks
Normal drinking water without 4NQO is in favor of the formation of esophagus squameous epithelial tumor, and 4NQO is a kind of nicotinoids chemical carcinogen,
In drinking-water very low dosage just can specificity in oesophagus formation tumour, its forming process and morphological change are and people's oesophagus unicorn shape
Cell cancer generating process is quite similar, and the model is the ideal model for studying oesophagus carcinogenesis and carcinogenesis mechanism.
When 2.3 experiments were carried out to 32 weeks, put to death two groups of mouse and take mouse oesophagus to take pictures, work as shown in Fig. 2 result is shown
When only with 4NQO feeding mouse, tumour number is more on mouse oesophagus；It is small when dextromethorphan is injected intraperitoneally while feeding 4NQO
Tumour number is significantly reduced on mouse oesophagus, it was demonstrated that dextromethorphan is notable to the prevention effect of tumour.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than the present invention is protected
The limitation of scope is protected, although being explained in detail with reference to preferred embodiment to the present invention, one of ordinary skill in the art should
Understand, technical scheme can be modified or equivalent substitution, without departing from the essence of technical solution of the present invention
And scope.
Claims (5)
1. dextromethorphan is preparing the purposes in being used to prevent or treat the medicine of tumour.
2. purposes according to claim 1, it is characterised in that the tumour is Hepatic venous pressure gradient, breast cancer, stomach
Cancer, lung cancer, cancer of pancreas, colon cancer, carcinoma of endometrium, melanoma, oophoroma or prostate cancer.
3. purposes according to claim 1, it is characterised in that the effective dose that the dextromethorphan is used in vivo and in vitro is
10~23.33mg/Kg/7 days.
4. purposes according to claim 1, it is characterised in that the administering mode of the dextromethorphan includes injection, described
Injection includes intra-tumoral injection, intraperitoneal injection, is subcutaneously injected and is injected intravenously.
5. purposes according to claim 1, it is characterised in that the formulation of the dextromethorphan is tablet, capsule, dripping pill
Agent, oral liquid or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710384984.1A CN107157998A (en) | 2017-05-26 | 2017-05-26 | The new application of dextromethorphan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710384984.1A CN107157998A (en) | 2017-05-26 | 2017-05-26 | The new application of dextromethorphan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107157998A true CN107157998A (en) | 2017-09-15 |
Family
ID=59820776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710384984.1A Pending CN107157998A (en) | 2017-05-26 | 2017-05-26 | The new application of dextromethorphan |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107157998A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1653050A (en) * | 2002-05-17 | 2005-08-10 | 詹肯生物科学公司 | Opioid and opioid-like compounds and uses thereof |
-
2017
- 2017-05-26 CN CN201710384984.1A patent/CN107157998A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1653050A (en) * | 2002-05-17 | 2005-08-10 | 詹肯生物科学公司 | Opioid and opioid-like compounds and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104323987B (en) | Mequindox injection and preparation method thereof | |
| JP2017513460A (en) | Use of short-term fasting regimens in combination with kinase inhibitors to enhance the efficacy and feasibility of conventional chemotherapeutic agents and reverse the side effects of kinases in normal cells and tissues | |
| CN107157998A (en) | The new application of dextromethorphan | |
| KR20120085353A (en) | pathogenic avian influenza medicine | |
| CN109820851A (en) | Application of the Rui Gefeini hydrate in preparation treatment pulmonary fibrosis disease drug | |
| KR20140058435A (en) | Honey composition with l-alanyl-l-glutamine | |
| CN104547289B (en) | Traditional Chinese medicine composition with effect of treating kidney injury caused by cisplatin | |
| CN108219024B (en) | Calophyllum inophyllum flower polysaccharide, extraction method thereof and application thereof in preparing medicine for treating functional constipation | |
| CN108042545B (en) | Application of azelastine hydrochloride in preparation of medicine for inhibiting growth of colon cancer tumor | |
| CN1867573A (en) | Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(iv) salts and derivatives and their use for the preparation of pharmaceutical active agents | |
| CN102335218B (en) | Pharmaceutical composition composed of arsenic trioxide and Nandina domestica, its preparation method and its application | |
| CN107233542B (en) | Application of longhurendan in preparing medicine for preventing and/or treating hepatic fibrosis | |
| CN110179915A (en) | Application of the Shenmai injection in the drug resistance drug that preparation reverses antineoplastic | |
| CN103622908B (en) | A kind of veterinary enrofloxacin micro emulsion and preparation method thereof | |
| CN109369727A (en) | A kind of anti cancer target complex and its preparation method and application | |
| CN102028674A (en) | Application of needle-leaved polyprenol in preparing medicines for preventing and treating Alzheimer disease | |
| CN108042540B (en) | Application of penfluridol in preparation of medicine for treating esophageal cancer | |
| CN102743469B (en) | New use of Hedyotis hedyotidea (DC.) Merr. for treating diseases | |
| CN109289022A (en) | A kind of pharmaceutical formulation inhibiting Colon and rectum adenoma | |
| CN109528758A (en) | A kind of composition improving sleep | |
| JP5875660B2 (en) | Anticancer drug side effect inhibitor and prognosis improving agent | |
| CN103750916A (en) | Building method of mouse stomach cancer model | |
| EP2968398B1 (en) | Modified hyaluronan and uses thereof in cancer treatment | |
| CN101375859A (en) | Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock | |
| Sun et al. | HCQ alleviates 5-FU-induced intestinal inflammation through inhibiting TLR9-dependent DNA sensing pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170915 |
|
| RJ01 | Rejection of invention patent application after publication |